tiprankstipranks
Trending News
More News >

Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment

Story Highlights
Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment

Confident Investing Starts Here:

An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.

Ascletis Pharma Inc. announced positive interim results from its U.S. Phase Ib trial of ASC30, a potentially first-in-class subcutaneous injection small molecule GLP-1R agonist. The trial demonstrated a 36-day half-life for one formulation, supporting less frequent administration, and showed a favorable safety profile with no serious adverse events. This advancement could enhance Ascletis’ positioning in the obesity treatment market, offering a novel therapeutic option with both oral and injectable formulations.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on the development of innovative drugs for the treatment of diseases such as obesity. The company specializes in creating small molecule therapeutics, with a particular emphasis on GLP-1 receptor agonists, and operates within the global pharmaceutical market.

YTD Price Performance: 147.51%

Average Trading Volume: 6,073,762

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.21B

For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App